Blueprint Medicines News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.02.24	Blueprint Medicines Q4 Loss decreases, beats estimates (RTTNews)
16.12.23	These Biotech Stocks Caught Our Attention - Did You Notice? (RTTNews)
12.12.23	Blueprint Medicines Announces European Commission Approval For AYVAKYT - Quick Facts (RTTNews)
10.11.23	Blueprint's Ayvakyt Receives Positive CHMP Opinion For Indolent Systemic Mastocytosis Treatment (RTTNews)
23.10.23	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire)
10.02.23	Blueprint Medicines Says FDA Places Partial Clinical Hold On Phase 1/2 VELA Trial Of BLU-222 (RTTNews)
23.01.23	Blueprint Medicines: FDA Grants Priority Review For Supplemental New Drug Application For AYVAKIT (RTTNews)
29.08.22	ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC (PR Newswire)
17.08.22	Blueprint Medicines: AYVAKIT PIONEER Trial Meets Primary, Key Secondary Goals In SM Patients (RTTNews)
03.08.22	ATRC Sees 18-21% Revenue Growth, EVH Q2 Results Beat Estimates, EXAS Trims Outlook, HRMY On Watch... (RTTNews)
30.06.22	Blueprint Medicines Enters Financing Collaborations With Sixth Street And Royalty Pharma (RTTNews)
04.05.22	ATRC Sees 16-20% Revenue Growth, RIGL On Watch, LUNG Breathes Easy, BPMC Braces For Busy Year (RTTNews)
25.03.22	Blueprint Medicines: EU Approves AYVAKYT For Treatment Of Adults With Advanced Systemic Mastocytosis (RTTNews)
16.02.22	Blueprint Medicines Slips As Loss Widens In Q4, Missing Estimates (RTTNews)
28.01.22	Blueprint Medicines Reports Positive CHMP Opinion To Expand Current Indication For AYVAKYT (RTTNews)
29.11.21	Blueprint To Buy Privately Held Lengo For Up To $465 Mln (RTTNews)
17.09.21	Roche Announces Positive CHMP Opinion For Gavreto In RET Fusion-positive Advanced NSCLC (RTTNews)
04.08.21	Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
29.07.21	Blueprint Medicines Reports Second Quarter 2021 Financial Results (PR Newswire)
28.07.21	MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development (PR Newswire)
22.07.21	Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021 (PR Newswire)
16.06.21	FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis (PR Newswire)
22.09.20	Stock Alert: Blueprint Medicines Jumps 10% (RTTNews)
15.07.20	AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On Watch (RTTNews)
14.07.20	Roche Enters Deal With Blueprint Medicines To Gain Co-development Rights For Pralsetinib (RTTNews)
02.07.20	LMNL Joins COVID-19 Battle, PFE/BNTX Vaccine Data Promising, EVLO On Watch (RTTNews)
29.04.20	BPMC's VOYAGER Fails, CLSD's NDA Resubmission Faces Delay, SNDX Hits New High (RTTNews)
28.04.20	Blueprint: Avapritinib Trial Fails To Meet Primary Endpoint - Quick Facts (RTTNews)
28.04.20	Biotech Stocks Facing FDA Decision In May 2020 (RTTNews)
12.02.20	Stock To Watch: Blueprint Medicines (BPMC) (RTTNews)
10.01.20	AGTC Catches Eyes, PTLA Bleeds As Antidote Sales Disappoint, RARE Jumps (RTTNews)
29.10.19	Top 5 Losers In Healthcare Sector (AGRX, MRUS, BPMC…) (RTTNews)
29.03.19	ARDS On The Move, GLPG Reports Positive Data, PRTO Plunges On PATENCY-2 Results (RTTNews)
03.12.18	XLRN On Watch, BPMC Makes An Imprint, Osteoporosis Drug Evenity Faces FDA Panel (RTTNews)
10.11.18	Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) (RTTNews)
07.10.18	Week Ahead In Pharmaceuticals: 6 Stocks To Watch (BPMC, BHC, ACRX...) (RTTNews)
02.08.18	ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches Eyes (RTTNews)
15.06.18	Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity (PR Newswire)
09.06.18	An Ear To The Pharma: 8 Stocks To Watch (CMRX, CRBP, KPTI, VRX…) (RTTNews)
04.06.18	Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China (PR Newswire)
31.05.18	Blueprint Medicines to Present at Upcoming Investor Conferences in June (PR Newswire)
29.05.18	Harvard-Incubated Expercoin Protocol to Launch a Network of Decentralized Learning Economies on the Blockchain (PR Newswire)
17.05.18	Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and... (PR Newswire)
02.05.18	Blueprint Medicines Reports First Quarter 2018 Financial Results (PR Newswire)
25.04.18	Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018 (PR Newswire)
17.04.18	CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark (RTTNews)
15.04.18	Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 (PR Newswire)
15.04.18	Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors (PR Newswire)
08.04.18	An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) (RTTNews)
14.03.18	Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	78.90	1.18 %	K V
CieFinRichemont	165.85	1.10 %	K V
Holcim	88.12	0.80 %	K V
Sonova Hldg	306.60	0.79 %	K V
Lonza Grp	567.00	0.67 %	K V
Geberit	505.60	-0.16 %	K V
Nestle	74.18	-0.38 %	K V
Sika	226.20	-0.44 %	K V
UBS Group	31.61	-0.44 %	K V
Kuehne+Nagel Int	205.30	-0.68 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Blueprint Medicines Corp

Aktien Top/Flop

Meistgelesene Nachrichten